Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Yogesh Punekar"'
Autor:
Wendy Davis, Andrea Mantsios, Tahilin Karver, Miranda Murray, Yogesh Punekar, Douglas Ward, U Fritz Bredeek, Santiago Moreno, Dolores Merino, Hernando Knobel, Antonio Campis, Deanna Kerrigan
Publikováno v:
PLoS ONE, Vol 15, Iss 5, p e0232473 (2020)
BACKGROUND:Two-drug regimens (2DR) to treat HIV infection have the potential to reduce long-term toxicity and increase therapeutic options for people living with HIV (PLHIV). Prior phase III trials, SWORD-1 and SWORD-2, as well as GEMINI-1 and GEMINI
Externí odkaz:
https://doaj.org/article/7ba2aefdbf37408397098fc3abdba01d
Autor:
Jason Foo, Sarah H Landis, Joe Maskell, Yeon-Mok Oh, Thys van der Molen, MeiLan K Han, David M Mannino, Masakazu Ichinose, Yogesh Punekar
Publikováno v:
PLoS ONE, Vol 11, Iss 4, p e0152618 (2016)
BACKGROUND:The Continuing to Confront COPD International Patient Survey estimated the prevalence and burden of COPD across 12 countries. Using data from this survey we evaluated the economic impact of COPD. METHODS:This cross-sectional, population-ba
Externí odkaz:
https://doaj.org/article/d5aadea06e2f41959cc0bce0cf33efa9
Autor:
V Chounta, D. Jha, A de Ruiter, J. Van Wyk, Shannon Ferrante, Lee Alexandra Evitt, Daniel Parks, M. Joshi, S Sharma, S Kaur, Yogesh Punekar, Matthew Radford
Publikováno v:
HIV Medicine
Objectives Dolutegravir (DTG) is widely recommended within three‐drug regimens. However, similar efficacy and tolerability have also been achieved with DTG within two‐drug regimens in clinical trials. This study evaluated the real‐world effecti
Autor:
Alan Oglesby, Karin Butler, Yogesh Punekar, Olivia Hayward, Lee Alexandra Evitt, Sarah-Jane Anderson, I. Jacob
Publikováno v:
Journal of managed carespecialty pharmacy. 27(7)
BACKGROUND: Dolutegravir(DTG)/lamivudine(3TC) is the first 2-drug regimen recommended as an initial treatment for people living with HIV (PLHIV). OBJECTIVE: To assess the cost-effectiveness and potential budget impact of DTG/3TC in the US healthcare
Autor:
Elmira Mamedova, Maria Claudia Nascimento, Fujie Zhang, Marcelo H. Losso, Jörg Sievers, Richard Kaplan, Judy Hopking, Dannae Brown, Mark R. Underwood, Ploenchan Chetchotisakd, Johannes Lombaard, Kimberly Y. Smith, Yogesh Punekar, Michael Aboud, Martin Gartland, Carlos Brites, José A Hidalgo
Publikováno v:
The Lancet Infectious Diseases. 19:253-264
Doubts exist regarding optimal second-line treatment options for HIV-1-infected patients in resource-limited settings. We assessed safety and efficacy of dolutegravir compared with ritonavir-boosted lopinavir, plus two nucleoside reverse transcriptas
Autor:
Bernard Aguilaniu, Johanna Despres, Gaëlle Nachbaur, Geoffray Bizouard, Robert Wood, Wilhelmine Meeraus, Afisi S. Ismaila, Sarah H. Landis, Rafal Jakubanis, Yogesh Punekar, Tim Holbrook, Camille Correia Da Silva
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Wilhelmine Meeraus,1 Robert Wood,2 Rafal Jakubanis,2 Tim Holbrook,2 Geoffray Bizouard,3 Johanna Despres,3 Camille Correia Da Silva,4 Gaelle Nachbaur,4 Sarah H Landis,1 Yogesh Punekar,5 Bernard Aguilaniu,6 Afisi S Ismaila7,8 1GlaxoSmithKline, Stockley
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-3 (2021)
An amendment to this paper has been published and can be accessed via the original article.
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-11 (2021)
Background The objective of this study was to assess the durability of response of dolutegravir (DTG) as an antiretroviral core agent by comparing its efficacy and safety with other recommended or commonly used core agents up to 96-weeks (W96). Metho
Autor:
Benjamin Young, Chinyere Okoli, Brent Allan, Bruce Richman, Marvelous Muchenje, Giulio Maria Corbelli, W. David Hardy, Erika Castellanos, Nicolas Van de Velde, Yogesh Punekar, Patricia de los Rios
Publikováno v:
Preventive medicine. 139
Modern antiretroviral therapy (ART) has improved the lives of people living with HIV (PLHIV) but currently requires daily adherence. We assessed prevalence and correlates of suboptimal adherence, and measured associations with self-reported health ou
Autor:
Phil McEwan, Alan Oglesby, Daniel Sugrue, Sara Lopes, Thomas Ward, Sarah-Jane Anderson, Olivia Hayward, Yogesh Punekar
Publikováno v:
Journal of managed carespecialty pharmacy. 26(2)
As life expectancy of patients infected with human immunodeficiency virus (HIV) approaches that of the general population, the composition of HIV management costs is likely to change.To (a) review treatment and disease management costs in HIV, includ